Transthyretin Amyloidosis and the Kidney

Luísa Lobato[*†‡] *and Ana Rocha*[*]

Summary
The amyloidoses are protein-misfolding disorders associated with progressive organ dysfunction. Immunoglobulin light chain is the most common, amyloid A the longest recognized, and transthyretin-associated amyloidosis (ATTR) the most frequent inherited systemic form. Although ATTR, an autosomal-dominant disease, is associated with at least 100 different transthyretin (TTR) mutations, the single amino-acid substitution of methionine for valine at position 30 is the most common mutation. Each variant has a different organ involvement, although clinical differences attributed to environmental and genetic factors exist within the same mutation. Peripheral neuropathy and cardiomyopathy are broadly described, and insights into disease reveal that kidney impairment and proteinuria are also clinical features. This review combines clinical and laboratory findings of renal involvement from the main geographic regions of disease occurrence and for different mutations of TTR. Fifteen nephropathic variants have been described, but the TTR V30M mutation is the best documented. Nephropathy affects patients with late-onset neuropathy, low penetrance in the family, and cardiac dysrhythmias. Micro-albuminuria can be the disorder's first presentation, even before the onset of neuropathy. Amyloid renal deposits commonly occur, even in the absence of urinary abnormalities. The experience with renal replacement therapy is based on hemodialysis, which is associated with poor survival. Because TTR is synthesized mainly in the liver, liver transplantation has been considered an acceptable treatment; simultaneous liver-kidney transplantation is recommended to avoid recurrence of nephropathy. In addition, the kidney-safety profile of new drugs in development may soon be available.

*Department of Nephrology and †Unidade Clínica de Paramiloidose, Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal; and ‡Unidade Multidisciplinar de Investigação Biomédica, ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

Correspondence:
Dr. Luísa Lobato, Department of Nephrology, Hospital de Santo António, Centro Hospitalar do Porto Largo Prof. Abel Salazar, 4099-001 Porto, Portugal. Email: lmlobato@icbas.up.pt

Introduction

Amyloidosis is caused by extracellular deposition of misfolded proteins as insoluble amyloid fibrils that progressively disrupt tissue structure and function.

The most common forms of systemic amyloidosis are associated with plasma cell dyscrasias (AL and AH amyloidosis), chronic inflammation (AA amyloidosis), dialysis (β_2-microglobulin amyloidosis), age (senile systemic amyloidosis), and inherited gene mutations. Proteins that cause familial forms of amyloidosis are transthyretin (TTR), apolipoprotein-AI, apolipoprotein-AII, gelsolin, fibrinogen Aα-chain, lysozyme, and cystatin C. All except the cystatin C clinically affect the kidney. The recently described leukocyte chemotactic factor 2 (LECT2), which has no evident familial trait, is also included in the nephropathic forms of systemic amyloidosis.

Most hereditary amyloidoses are due to TTR mutations. Although kidney deposits were recognized in the original description of the disease (1), a renal phenotype of TTR amyloidosis (ATTR) has been overlooked. This review discusses the effects of ATTR on the kidney, with special attention to the most common mutation, V30M (c.148G>A, p.Val50Met, applying the new nomenclature of the Human Genome Variation Society). The introduction of new therapies will also be reviewed.

Transthyretin

TTR is one of most abundant circulating proteins belonging to a subset of 25 proteins with a predisposition to misfold. It is synthesized by the liver (90%), retina, pancreas, and choroid plexus as a 55-kD tetramer with four identical 127-residue β-sheet–rich subunits and a 20-residue signal peptide with no specific physiologic properties (2,3). TTR mRNA has been found in kidney cells (4). TTR binds to thyroxine and retinol-binding protein in the blood and cerebrospinal fluid and transports vitamin A without the loss of retinol-binding protein molecules in the kidney (5).

The TTR gene is located on human chromosome 18 (18q11.2-q12.1) (6), and more than 100 different single- or double-point mutations and a deletion are described. Pathogenic mutations are associated with the fibrillar conformation of proteins and, subsequently, amyloidosis. Amino acid substitutions result in conformational changes in the protein that lead to weaker subunit interactions between the tetramers. The dissociation into monomers is the first step in the development of amyloidosis. Modified soluble tetramers exposing cryptic epitopes appear to circulate in patients, but the trigger leading to dissociation into monomeric and oligomeric intermediates is not completely understood.

Fibrillar deposits are formed only in mid- to late adulthood. This could be because the mechanisms that promote amyloidogenesis become more active with aging or the preventive factors become less effective with increasing age. Nonmutated TTR also forms deposits, suggesting that mutations are not the sole determining factor in amyloid fibril formation and that

wild-type (WT) TTR has an intrinsic amyloidogenic property (7).

Deposition of WT-TTR results in senile systemic amyloidosis (SSA), whereas its variants or fragments are associated with forms that are transmitted in an autosomal-dominant manner. Some nonpathogenic gene mutations appeared to provide a protective effect with a slower disease progression (8). Because the liver is the main source of circulating TTR, orthotopic liver transplantation (OLT) was proposed for treatment of ATTR (9).

Epidemiology and Genetics

ATTR is the most common form of hereditary amyloidosis. This disease was described by Andrade in Portugal (1) and was later reported in Sweden (10) and Japan (11). The initial reports of ATTR emphasized peripheral neuropathy, leading to the term *familial amyloidotic polyneuropathy* (FAP); that condition affects 1/100,000 people, although this number varies by country (12). In an endemic area of Portugal, the prevalence of ATTR V30M is 1/1000, which is similar to its prevalence in Sweden (13,14). The mutations with predominant heart manifestations include the ATTR I111M and the ATTR V122I, which are present in 3.5% of the African-American population (15). Although the TTR mutation is required for amyloidosis, carriers of the same mutation present variable penetrance. This characteristic suggests that genetic modifiers, epigenetic factors (16), or environmental influence exist. Several candidate genes have been hypothesized but none have been identified (17). On the basis of the finding that penetrance is higher when the disease is maternally inherited, it was recently suggested that a mitochondrial polymorphism might partially explain differences in penetrance (18). Studies on the influence of environmental factors in kidney amyloidosis are contradictory. Renal deposits in transgenic mice expressing the human TTR gene were absent in specific pathogen-free conditions (19) but persisted in other experimental evaluations under the same environment (20).

There is a slight male predominance of ATTR V30M, except in nonendemic areas of Japan where women are rarely affected (21). Epidemiologic differences, shown in Table 1, have a special importance in nephropathy (22).

Clinical Presentation

Ethnicity and the TTR variant affect organ involvement, although differences exist between patients with the same mutation and within the same family (Table 2).

The principal manifestation of most ATTR amyloidosis is peripheral neuropathy with dysautonomia. In the era before OLT, patients died on average 11 years after disease onset (23). The age of onset ranges from 17 to 80 years (12). In Portugal and Japan, disease caused by the ATTR V30M variant usually develops between the third and fourth decades of life. Complement factor C1Q polymorphisms may modulate the age of onset and explain genetic anticipation with amyloid deposition at an earlier age in successive generations (24). In monozygotic twins from Spain, different ages of onset and phenotypes, including dissimilar kidney involvement, have been reported (25). Of note, homozygosity was not described as conferring a worse prognosis of nephropathy in Swedish (26) and Japanese (27) populations.

Table 1. Characteristics of transthyretin-associated amyloidosis V30M with nephropathy

Epidemiology and Genetics	Findings
Origin	Nonendemic areas
Family history	Frequently absent
Gender predominance	Female
Age of onset of neuropathy	>40 yr confers 3.5-fold increased risk for nephropathy
Clinical anticipation within the family	Frequently present
Familial aggregation of nephropathy	Present especially in siblings of ESRD probands

Source: Lobato L, Beirão I, Silva M et al: End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. *Amyloid* 11: 27–37, 2004.

Non-neurologic features include involvement of the heart, eye, gastrointestinal tract, and kidney. A small number of ATTR V30M cases, especially late-onset cases, may present with heart failure (28). Precocious anemia, unrelated to renal manifestations, is conferred by low erythropoietin levels (29,30). It was suggested that the distal nephron is the major site of erythropoietin production in ATTR (31).

Renal Manifestations

Much of the literature on renal involvement in ATTR is based on small series. The assessment of different mutations is not homogeneous; some reports specify the clinical manifestations, and others simply describe the presence of renal amyloid deposits. The distribution of amyloid within organs can be demonstrated using ^{123}I conjugated with serum amyloid P component, a glycoprotein present in all amyloid deposits (32). Although scintigraphy with ^{123}I serum amyloid P component can depict extensive amyloid deposits in organs in which they have not been suspected clinically, there is a poor correlation with the severity of organ dysfunction. In addition, this modality is unavailable in most centers (33).

The first study dedicated to renal involvement in ATTR V30M was conducted in Sweden (10). Serum creatinine was increased in 5 of the 26 patients examined, and uremia contributed to death in 4 of them. Another study from Sweden, which included 24 patients, showed that half had renal insufficiency and proteinuria (34). Nephropathy did not correlate with age, duration of disease, or severity of neuropathy. In Japan, early manifestation of heavy proteinuria was also identified (35). A Portuguese prospective study (36) involving 22 asymptomatic TTR V30M gene carriers and 32 patients with neuropathy showed that microalbuminuria appears within the third and fifth years of disease and can precede the onset of neuropathy. After microalbuminuria, overt nephropathy developed in half of the patients, usually 2 years later. Renal failure generally occurred 5 years after microalbuminuria, and even sooner in women. The average duration of neuropathy at

Table 2. TTR variants with kidney involvement

TTR Variant	DNA Nucleotide Nomenclature	Phenotype	Kidney	Geographic Focus	Reference
Val30Met (p.Val50Met)	c.148G>A	PN, AN, eye, kidney	Proteinuria, CRF, amyloid deposits, ^{123}I-SAP	Portugal, Japan, Sweden, USA, Mallorca, Cyprus	63
Val30Ala (p.Val50Ala)	c.149T>C	Heart, AN, PN, kidney	Amyloid deposits	USA, Germany, China	64
Phe33Cys (p.Phe53Cys)	c.158T>G	CTS, heart, eye, kidney	Amyloid deposits	USA	65
Phe33Ile (p.Phe53Ile)	c.157T>A	PN, AN, eye, kidney	Amyloid deposits	Poland	66
Gly47Glu (p.Gly67Glu)	c.200G>A	Heart, PN, AN, kidney	CRF, amyloid deposits, ^{123}I-SAP	Turkey, USA, Germany	67
Ser52Pro (p.Ser72Pro)	c.214T>C	PN, AN, heart, kidney	CRF, amyloid deposits	UK, Portugal	68
Gly53Glu (p.Gly73Glu)	c.218G>A	Heart, kidney	CRF	Sweden, Basque	69
Ile73Val (p.Ile93Val)	c.277A>G	PN, AN, kidney	CRF	Bangladesh	70
Ser77Tyr (p.Ser97Tyr)	c.290C>A	Heart, kidney, PN	CRF	USA, France, Germany	71
Tyr78Phe (p.Tyr98Phe)	c.293A>T	PN, CTS, skin, heart	CRF	France, Italy	72
His88Arg (p.His108Arg)	c.323A>G	PN, heart, kidney	CRF	Sweden	69
Glu92Lys (p.Gln112Lys)	c.334G>A	Heart, kidney	Amyloid deposits	Japan	73
Val94Ala (p.Val114Ala)	c.341T>C	Heart, PN, AN, kidney	Amyloid deposits	Germany, USA	74
Ser112Ile (p.Ser132Ile)	c.395G>T	PN, heart, kidney	CRF	Italy	75
Asn124Ser (p.Asn154Ser)	c.371A>G	Kidney, heart	Proteinuria, amyloid deposits	Italy	76

PN, peripheral neuropathy; AN, autonomic neuropathy; ^{123}I-SAP, kidney deposits in scintigraphy with ^{123}I-labeled serum amyloid P component; USA, United States of America; CTS, carpal tunnel syndrome; eye, vitreous opacities; CRF, chronic renal failure.

first dialysis was 10 years. In the pre-OLT era, a serial study involving 403 Portuguese patients from 150 kindreds showed that one third of the patients presented proteinuria and 10% progressed to ESRD (22,37). Proximal tubular syndromes were never assigned to ATTR V30M.

The ATTR variants with renal involvement are detailed in Table 2. Proteinuria was not reported in SSA (WT-TTR) or TTR-associated cardiomyopathy.

Renal Pathology

In transgenic mice, WT and variant TTR are present in the kidney in fibrillar and nonfibrillar aggregates (38). In FAP, the deposition of TTR in cell culture in the form of small toxic nonfibrillar aggregates may occur before amyloid formation (39), suggesting that prefibrillar oligomers can cause cell death. Mice with multiple copies of the WT human TTR gene showed nonfibrillar, noncongophilic anti-human TTR-positive deposits in a smooth pattern along the glomerular and tubular basement membranes. Older animals developed dense congophilic amyloid deposits in the glomeruli and focal deposits in the interstitium. Of note, in elderly Swedish patients with SSA (WT-TTR), postmortem analysis revealed minimal congophilic material in the renal cortex, although, as previously mentioned, SSA is not associated with proteinuria (40). Some authors associate weak Congo red staining of the fibrils with delayed disease onset and associate a strong affinity to Congo red with early presentation of the disease (41). In the kidney, staining characteristics of amyloid deposits were not described as being different in cases of early- and late-onset neuropathy.

A crucial matter in ATTR nephropathy is recognizing the presence and distribution of renal amyloid deposits. Four studies systematically evaluated the renal histopathology in ATTR V30M. Of those, three were concerned with 14 patients of Portuguese origin each and the other with 13 Japanese cases.

In one report, in which half the patients studied had normoalbuminuria, amyloid was found in all cases (42). In another report, which involved only 4 patients with proteinuria, 13 of the 14 patients had amyloid deposits (36). A third study demonstrated the presence of deposits in all patients, even in the 9 in whom proteinuria was absent (43). Finally, in the Japanese cohort, there was evidence of amyloid in 12 cases; proteinuria was verified in 5 of these cases (44).

Patients with albuminuria had a more extensive amyloid involvement than those without clinical renal disease. The medulla, basement membrane of distal tubules, loops of

Figure 1. | **Light microscopy findings in transthyretin-associated amyloidosis (ATTR) showing that amyloid deposition can be found in glomeruli, vasculature, and tubulointerstitium.** (A) Massive deposits in the glomerulus, ATTR V30M-amyloidosis, antitransthyretin (TTR) fixation (immunoperoxidase technique; original magnification, ×400). (B) Deposits in the arteriole at the vascular pole–sparing mesangial areas, ATTR V30M-amyloidosis (Congo red; original magnification, ×400). (C) Amyloid in a blood vessel in conjunction with glomerular deposits, ATTR V30M-amyloidosis (Congo red–stained material under polarized light leads to apple-green birefringence; original fixation, ×200). (D) Heavy amyloid infiltration of a blood vessel in ATTR V30M-amyloidosis (Congo red–stained material under polarized light; original fixation, ×400). (E) Congo red positivity in the medullary interstitium, an early lesion in ATTR V30M-amyloidosis (original magnification, ×100). (F) Anti-TTR fixation in the tubular basement membrane, ATTR S52P-amyloidosis (immunoperoxidase technique; original magnification, ×1000).

Henle, and interstitium are typically filled with amyloid, even in the early stages of the disease. Proximal tubules positively react with anti-TTR antibody inside the cells, which can be sustained by internalization of TTR by megalin (45,46).

Renal dysfunction and the degree of proteinuria are correlated with heavy amyloid deposition in the glomeruli, arterioles, and medium vessels, but not with deposition in medullary tissues (42). Renal deposition does not parallel that of myelinated nerve fiber loss in the sural nerve, suggesting that evolution and severity of nephropathy are not correlated with the degree of neuropathy (21,44,47).

Amyloid was found predominantly in vessels and tubular basement membrane in ATTR S52P. Detailed pathologic descriptions of other variants are not available.

The first case of *de novo* ATTR in a renal graft was observed in an asymptomatic gene carrier for TTR V30M 13 years after transplantation (Lobato L, unpublished data). In this case, primary GN led to ESRD. Figure 1 shows patterns of amyloid deposition in ATTR amyloidosis.

Treatment of ESRD

To date, only one published study has evaluated ATTR patients undergoing long-term dialysis (48). This report included 62 patients with ATTR V30M who initiated dialysis at a mean age of 52 years. The main indications for dialysis were fluid overload and metabolic acidosis. Average survival after initiation of hemodialysis was 21 months, with septicemia being the leading cause of death. Decubitus ulcers, followed by catheter sepsis and pneumonia, were the major sources of infections; untreatable hypotension and cachexia were additional causes of death. Symptomatic intradialytic hypotension was present in more than half of all patients and predominated in patients with native arteriovenous fistula thrombosis.

In patients who did not survive beyond the first year of dialysis, the absence of a pacemaker represented a two-fold increased risk for death. This observation is probably related to reduced heart rate variability in the face of the combination of amyloidosis with uremia (49). As previously described, when the use of a pacemaker is advisable in patients with amyloidosis, the general recommendations must be followed; however, the threshold for implanting these devices is usually very low, given that other coexisting factors (autonomic neuropathy and hypoalbuminemia) exacerbate episodes of low cardiac output (50).

Gastrointestinal disturbances, malnutrition, and physical disability compromise self-peritoneal dialysis care, which requires assisted treatment. Peritoneal dialysis in ATTR is probably a residual treatment, and no sustained experience is reported.

The suitability of isolated kidney transplantation is compromised once constant production of the amyloidogenic precursor protein by the liver is maintained. In contrast to other types of hereditary nephropathic amyloidosis, in ATTR this approach was not attempted (51).

Treatment of ATTR

Currently, there is no specific therapy to remove existing amyloid deposits of any origin. Because the liver is the organ primarily responsible for the production of circulating precursor amyloidogenic protein in ATTR, OLT is performed as a potential curative treatment to eliminate the mutant TTR from plasma (52). In the first descriptions of this treatment, OLT was used to modify neuropathy progression (53). OLT outcomes are not always favorable, and even successful treatments are controversial in terms of nephropathy progression. Scintigraphy with ^{123}I serum amyloid P component showed mobilization of visceral amyloid, namely in the kidney, although mobilization of renal deposits by histology has never been proven (54). Support for *de novo* amyloid deposition was demonstrated by the type of fibrils extracted from the kidney before OLT (55). The fibrils did not contain obvious WT-TTR; however, after OLT, WT-TTR was evident, in a process similar to that in the heart, although in a less substantial amount. The analysis of fibrils extracted from myocardium tissue after OLT revealed a greatly increased ratio of WT to variant TTR, suggesting that pre-existing amyloid fibrils can induce the formation of rapidly progressive deposits (56). This unique vulnerability of heart tissue for continued deposition of WT-TTR is not understood (57).

During the first year after OLT, renal function significantly declined in Swedish patients, with stabilization thereafter (58). Portuguese studies demonstrated that proteinuria may be augmented, occur *de novo*, or remit. Long-term dialysis was implemented 7 years after OLT, although a substantial gain in survival was possible (59). In one patient, histologic assessment revealed more extensive deposits and interstitial nephritis.

Therefore, in the presence of progressive renal insufficiency or proteinuria, a kidney biopsy provides information that is useful for adjusting immunosuppressive therapy and determining whether heavy amyloid deposits are the main cause of ESRD. Japanese researchers recommended renal biopsy to determine the contraindications for liver transplantation (44). In a French study of eight patients who underwent a second renal biopsy 2 years after transplantation, no significant changes in deposits or toxicity due to calcineurin inhibitors were detected (43).

Simultaneous liver-kidney transplantation represents a therapy for ESRD and avoids recurrence of nephropathy. The Familial World Transplant Registry reports 32 such transplantations in patients with ATTR V30M and 1 in a patient with Val94Ala; in addition, a patient with Ser77Tyr underwent both liver-kidney transplantation and heart transplantation. In our center, six patients (mean duration of neuropathy, 8 years) had liver-kidney transplantation (60). After 84 months proteinuria had not recurred, but no histologic evaluation was done.

The use of FAP livers as allografts for other patients, also known as *domino transplantation*, has raised concerns about the risk for *de novo* disease (61). In our center, interstitial amyloidosis in the kidney was also demonstrated 8 years after a domino procedure (Vizcaíno R, unpublished data).

New strategies have been developed to treat FAP despite the scarcity of organs and doubts concerning long-term results (62). Several trials, some already completed and others recruiting participants, are evaluating or will evaluate new drugs (Table 3). A decision tree for ATTR amyloidosis is presented in Figure 2.

Table 3.   Treatment options for transthyretin-associated amyloidosis, classic therapy, and novel agents

Proposed Treatment	Action	Applicability	Reference
Liver transplantation (OLT)	Eliminate source of genetically variant protein	Clinical use	9
OLT + kidney transplant	Same as for OLT + therapy for ESRD	Clinical use	60
OLT + kidney transplant + heart transplant	Same as for OLT + therapy for ESRD and severe heart failure	Clinical use	77
Diflunisal	Binds to TTR *via* a T4-binding site stabilizing TTR tetramer	Clinical trial 250 mg twice day or 500 mg once day, oral	78
Diclofenac, flufenamic acid	Same as for diflunisal	Preclinical *In vitro* study	79
Trivalent chromium (Cr3+)	Facilitates binding of T4, (presumably) stabilizing TTR tetramer	Preclinical *Ex vivo* human clinical	80
Fx-1006A (tafamidis meglumine)	Prevents misfolding of the protein by stabilization of TTR tetramer	Clinical use 20 mg once day, oral	81
Cyclodextrin	Reduces amyloid deposits by decreasing conformational change of TTR	Preclinical *In vivo* transgenic mouse study	82
Doxycycline + TUDCA	Removes TTR toxic aggregates and disrupts TTR fibril	Clinical trial Doxycycline, 200 mg once day, + TUDCA, 750 mg once day, oral	83
bis-D-proline compound + anti-SAP antibodies	Disaggregates amyloid deposits through binding to high affinity to SAP; triggers its rapid clearance by the liver and triggers phagocytic clearance mechanisms by potent, complement-dependent, macrophage-derived giant-cell reaction	Pre-clinical *In vivo* transgenic mouse study	84
Carvedilol	Reduces amyloid deposits mediated by antioxidant effect	Preclinical *In vivo* transgenic mouse study	85
Epigallocatechin-3-gallate	Disaggregates amyloid deposits and decreases nonfibrillar TTR deposition	Preclinical *In vivo* transgenic mouse study	86
Monomers of T119M	Exchanges subunits to form highly stable heterotetramers that are less amyloidogenic	Preclinical *In vitro* study	87
Single-stranded oligonucleotides	Repairs genes (conversion of TTR gene)	Preclinical *In vivo* transgenic mouse study	88
Anti-sense oligonucleotides	Suppresses TTR mRNA Levels	Preclinical *In vivo* transgenic mouse study	89
TTR small interfering RNA (siRNA)	Inhibits TTR expression		90
ALN-TTR01: first-generation lipid nanoparticle		Clinical trial	
ALN-TTR02: second-generation lipid nanoparticle		Single endovenous dose	
ALN-TTRsc: subcutaneous		Clinical trial Single endovenous dose, >10- fold enhanced potency compared with ALN-TTR01 Preclinical *In vitro* study	

OLT, orthotopic liver transplantation; TTR, transthyretin; T4, thyroxine; TUDCA, tauroursodeoxycholic acid; SAP, serum amyloid P component.

Figure 2. | **Algorithm of diagnosis, treatment of nephropathy, and general recommendations for transthyretin-associated amyloidosis (ATTR).** The results of immunohistochemistry for ATTR can be equivocal and difficult to interpret. Recently, mass spectrometry based on proteomic methods has been applied to subtype amyloidosis. SSA, senile systemic amyloidosis; TTR, transthyretin.

Final Remarks

In ATTR, the occurrence and onset of nephropathy vary according to the mutation. The possibility of old asymptomatic gene carriers suggests that ATTR nephropathy may be present, regardless of its absence in family history. It is important to suspect ATTR in patients presenting with proteinuria, progressive renal failure, weight loss, peripheral neuropathy, and cardiac dysrhythmias.

Urinary biomarkers specific for tubular and interstitial pathologic abnormalities are needed for early detection and timely treatment. Until now, trials did not clarify whether kidney disease is an exclusion criterion for a drug or an option for a particular one. New therapies will highlight important issues for nephrologists and groups devoted to amyloidosis.

Disclosures
None.

References
1. Andrade C: A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. *Brain* 75: 408–427, 1952
2. Kanda Y, Goodman DS, Canfield RE, Morgan FJ: The amino acid sequence of human plasma prealbumin. *J Biol Chem* 249: 6796–6805, 1974
3. Costa RH, Lai E, Darnell JE Jr: Transcriptional control of the mouse prealbumin (transthyretin) gene: Both promoter sequences and a distinct enhancer are cell specific. *Mol Cell Biol* 6: 4697–4708, 1986
4. Mita S, Maeda S, Shimada K, Araki S: Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. *J Biochem* 100: 1215–1222, 1986
5. Goodman DS: Retinol-binding protein, prealbumin, and vitamin A transport. *Prog Clin Biol Res* 5: 313–330, 1976
6. Wallace MR, Naylor SL, Kluve-Beckerman B, Long GL, McDonald L, Shows TB, Benson MD: Localization of the human prealbumin gene to chromosome 18. *Biochem Biophys Res Commun* 129: 753–758, 1985
7. Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson DR, Tagoe C, Gallo G, Buxbaum J: Amyloid and non-fibrillar deposits in mice transgenic for wild-type human transthyretin: A possible model for senile systemic amyloidosis. *Lab Invest* 81: 385–396, 2001
8. Alves IL, Almeida MR, Skare J, Skinner M, Kurose K, Sakaki Y, Costa PP, Saraiva MJ: Amyloidogenic and non-amyloidogenic transthyretin Asn 90 variants. *Clin Genet* 42: 27–30, 1992
9. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, Andersen O, Karlberg I, Nordén G, Nakazato M, et al: Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). *Clin Genet* 40: 242–246, 1991
10. Andersson R: Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. *Acta Med Scand Suppl* 590[Suppl]: 1–64, 1976
11. Araki S: Type I familial amyloidotic polyneuropathy (Japanese type). *Brain Dev* 6: 128–133, 1984
12. Benson M: Amyloidosis. In: *The Metabolic & Molecular Bases of Inherited Disease*, edited by Scriver CR, 8th Ed., New York, McGraw-Hill, 2001, pp 5345–5378
13. Sousa A, Coelho T, Barros J, Sequeiros J: Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). *Am J Med Genet* 60: 512–521, 1995
14. Sousa A, Andersson R, Drugge U, Holmgren G, Sandgren O: Familial amyloidotic polyneuropathy in Sweden: Geographical distribution, age of onset, and prevalence. *Hum Hered* 43: 288–294, 1993
15. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN: Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. *N Engl J Med* 336: 466–473, 1997
16. Olsson M, Norgren N, Obayashi K, Plante-Bordeneuve V, Suhr OB, Cederquist K, Jonasson J: A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. *BMC Med Genet* 11: 130, 2010
17. Soares ML, Coelho T, Sousa A, Batalov S, Conceição I, Sales-Luís ML, Ritchie MD, Williams SM, Nievergelt CM, Schork NJ, Saraiva MJ, Buxbaum JN: Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: Complexity in a single-gene disease. *Hum Mol Genet* 14: 543–553, 2005
18. Bonaïti B, Olsson M, Hellman U, Suhr O, Bonaïti-Pellié C, Planté-Bordeneuve V: TTR familial amyloid polyneuropathy: Does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? *Eur J Hum Genet* 18: 948–952, 2010
19. Inoue S, Ohta M, Li Z, Zhao G, Takaoka Y, Sakashita N, Miyakawa K, Takada K, Tei H, Suzuki M, Masuoka M, Sakaki Y, Takahashi K, Yamamura K: Specific pathogen free conditions prevent transthyretin amyloidosis in mouse models. *Transgenic Res* 17: 817–826, 2008
20. Tagoe CE, Jacobson DR, Gallo G, Buxbaum JN: Mice transgenic for human TTR have the same frequency of renal TTR deposition whether maintained in conventional or specific pathogen free environments. *Amyloid* 10: 262–266, 2003
21. Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, Takei Y, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G: Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. *Brain* 122: 1951–1962, 1999
22. Lobato L: Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M). *J Nephrol* 16: 438–442, 2003
23. Sousa A, Coelho T, Morgado R, Coutinho P: Statistical analysis of factors which may influence the duration of familial amyloidostic polyneuropathy type I. In: Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders, edited by Costa PP, Falcão A, Saraiva MJ, Porto, Portugal, Arquivos de Medicina, 1990, pp 351–355
24. Dardiotis E, Koutsou P, Zamba-Papanicolaou E, Vonta I, Hadjivassiliou M, Hadjigeorgiou G, Cariolou M, Christodoulou K, Kyriakides T: Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. *J Neurol Sci* 284: 158–162, 2009
25. Munar-Qués M, López Domínguez JM, Viader-Farré C, Moreira P, Saraiva MJ: Two Spanish sibs with familial amyloidotic polyneuropathy homozygous for the V30M-TTR gene. *Amyloid* 8: 121–123, 2001
26. Holmgren G, Haettner E, Nordenson I, Sandgren O, Steen L, Lundgren E: Homozygosity for the transthyretin-met30-gene in two Swedish sibs with familial amyloidotic polyneuropathy. *Clin Genet* 34: 333–338, 1988
27. Yoshinaga T, Nakazato M, Ikeda S, Ohnishi A: [Three siblings homozygous for the transthyretin-Met30 gene in familial amyloidotic polyneuropathy—evaluation of their clinical pictures with reference to those of other 10 cases reported]. *Rinsho Shinkeigaku* 34: 99–105, 1994
28. Conceição I, De Carvalho M: Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal. *Muscle Nerve* 35: 116–118, 2007
29. Beirão I, Lobato L, Costa PM, Fonseca I, Mendes P, Silva M, Bravo F, Cabrita A, Porto G: Kidney and anemia in familial amyloidosis type I. *Kidney Int* 66: 2004–2009, 2004
30. Beirão I, Moreira L, Porto G, Lobato L, Fonseca I, Cabrita A, Costa PM: Low erythropoietin production in familial amyloidosis TTR V30M is not related with renal congophilic amyloid deposition. A clinicopathologic study of twelve cases. *Nephron Clin Pract* 109: c95–c99, 2008
31. Beirão I, Moreira L, Barandela T, Lobato L, Silva P, Gouveia CM, Carneiro F, Fonseca I, Porto G, Pinho E Costa P: Erythropoietin production by distal nephron in normal and familial amyloidotic adult human kidneys. *Clin Nephrol* 74: 327–335, 2010
32. Hawkins PN, Lavender JP, Pepys MB: Evaluation of systemic amyloidosis by scintigraphy with ^{123}I-labeled serum amyloid P component. *N Engl J Med* 323: 508–513, 1990
33. Hawkins PN: Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. *Curr Opin Nephrol Hypertens* 11: 649–655, 2002
34. Steen L, Wahlin A, Bjerle P, Holm S: Renal function in familial amyloidosis with polyneuropathy. *Acta Med Scand* 212: 233–236, 1982
35. Ikeda S, Hanyu N, Hongo M, Yoshioka J, Oguchi H, Yanagisawa N, Kobayashi T, Tsukagoshi H, Ito N, Yokota T: Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. *Brain* 110: 315–337, 1987
36. Lobato L, Beirão I, Silva M, Bravo F, Silvestre F, Guimarães S, Sousa A, Noël LH, Sequeiros J: Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. *Nephrol Dial Transplant* 18: 532–538, 2003
37. Lobato L: A Nefropatia na Polineuropatia Amiloidótica Familiar de Tipo Português (TTR V30M). Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal, Universidade do Porto, 2004, p 207
38. Buxbaum J, Tagoe C, Gallo G, Reixach N, French D: The pathogenesis of transthyretin tissue deposition: Lessons from transgenic mice. *Amyloid* 10[Suppl 1]: 2–6, 2003

39. Sousa MM, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ: Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates. *Am J Pathol* 159: 1993–2000, 2001

40. Westermark P, Bergström J, Solomon A, Murphy C, Sletten K: Transthyretin-derived senile systemic amyloidosis: Clinicopathologic and structural considerations. *Amyloid* 10[Suppl 1]: 48–54, 2003

41. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P: Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. *J Pathol* 216: 253–261, 2008

42. Lobato L, Beirão I, Guimarães SM, Droz D, Guimarães S, Grünfeld JP, Noël LH: Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits. *Am J Kidney Dis* 31: 940–946, 1998

43. Snanoudj R, Durrbach A, Gauthier E, Adams D, Samuel D, Ferlicot S, Bedossa P, Prigent A, Bismuth H, Charpentier B: Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. *Nephrol Dial Transplant* 19: 1779–1785, 2004

44. Oguchi K, Takei Y, Ikeda S: Value of renal biopsy in the prognosis of liver transplantation in familial amyloid polyneuropathy ATTR Val30Met patients. *Amyloid* 13: 99–107, 2006

45. Sousa MM, Norden AG, Jacobsen C, Willnow TE, Christensen EI, Thakker RV, Verroust PJ, Moestrup SK, Saraiva MJ: Evidence for the role of megalin in renal uptake of transthyretin. *J Biol Chem* 275: 38176–38181, 2000

46. Sousa MM, Saraiva MJ: Internalization of transthyretin. Evidence of a novel yet unidentified receptor-associated protein (RAP)-sensitive receptor. *J Biol Chem* 276: 14420–14425, 2001

47. Takahashi K, Sakashita N, Ando Y, Suga M, Ando M: Late onset type I familial amyloidotic polyneuropathy: Presentation of three autopsy cases in comparison with 19 autopsy cases of the ordinary type. *Pathol Int* 47: 353–359, 1997

48. Lobato L, Beirão I, Silva M, Fonseca I, Queirós J, Rocha G, Sarmento AM, Sousa A, Sequeiros J: End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: Presentation, survival and prognostic factors. *Amyloid* 11: 27–37, 2004

49. Rubinger D, Sapoznikov D, Pollak A, Popovtzer MM, Luria MH: Heart rate variability during chronic hemodialysis and after renal transplantation: Studies in patients without and with systemic amyloidosis. *J Am Soc Nephrol* 10: 1972–1981, 1999

50. García-Pavía P, Tomé-Esteban MT, Rapezzi C: [Amyloidosis. Also a heart disease]. *Rev Esp Cardiol* 64: 797–808, 2011

51. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN: Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. *J Am Soc Nephrol* 20: 444–451, 2009

52. Ericzon BG, Holmgren G, Lundgren E, Suhr OB: New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umeå Sweden, June 1999. *Amyloid* 7: 145–147, 2000

53. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, Suhr OB: Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival. *Liver Transpl* 15: 1229–1235, 2009

54. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, et al: Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. *Lancet* 341: 1113–1116, 1993

55. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, Kawamorita A, Kanno H, Ikeda SI: Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. *Am J Transplant* 7: 235–242, 2007

56. Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, Harihara Y, Baba S, Kametani F, Ikeda S: Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. *Biochem Biophys Res Commun* 274: 702–706, 2000

57. Ihse E, Suhr OB, Hellman U, Westermark P: Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. *J Mol Med (Berl)* 89: 171–180, 2011

58. Nowak G, Suhr OB, Wikström L, Wilczek H, Ericzon BG: The long-term impact of liver transplantation on kidney function in familial amyloidotic polyneuropathy patients. *Transpl Int* 18: 111–115, 2005

59. Rocha A, Lobato L, Silva H, Beirão I, Santos J, Pessegueiro H, Almeida R, Cabrita A: Characterization of end-stage renal disease after liver transplantation in transthyretin amyloidosis (ATTR V30M). *Transplant Proc* 43: 189–193, 2011

60. Lobato L, Beirão I, Seca R, Pessegueiro H, Rocha MJ, Queiroz J, Gomes M, Henriques AC, Teixeira M, Almeida R: Combined liver-kidney transplantation in familial amyloidotic polyneuropathy TTR V30M: nephrological assessment. *Amyloid* 18 [Suppl 1]: 185–187, 2011

61. Conceição I, Evangelista T, Castro J, Pereira P, Silvestre A, Coutinho CA, de Carvalho M: Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation. *Muscle Nerve* 42: 836–839, 2010

62. Yamashita T, Ando Y, Uchino M: [Familial amyloid polyneuropathy]. *Brain Nerve* 63: 583–595, 2011

63. Saraiva MJ, Costa PP, Birken S, Goodman DS: Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. *Trans Assoc Am Physicians* 96: 261–270, 1983

64. Liu JY, Guo YJ, Zhou CK, Ye YQ, Feng JQ, Yin F, Jiang XM: Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family. *J Neurol Sci* 304: 83–86, 2011

65. Lim A, Prokaeva T, McComb ME, Connors LH, Skinner M, Costello CE: Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. *Protein Sci* 12: 1775–1785, 2003

66. Gafni J, Fischel B, Reif R, Yaron M, Pras M: Amyloidotic polyneuropathy in a Jewish family. Evidence for the genetic heterogeneity of the lower limb familial amyloidotic neuropathies. *Q J Med* 55: 33–44, 1985

67. Pelo E, Da Prato L, Ciaccheri M, Castelli G, Gori F, Pizzi A, Torricelli F, Marconi G: Familial amyloid polyneuropathy with genetic anticipation associated to a gly47glu transthyretin variant in an Italian kindred. *Amyloid* 9: 35–41, 2002

68. Booth DR, Soutar AK, Hawkins PN, Reilly M, Harding A, Pepys MB: Three new amyloidogenic transthyretin gene mutations advantages of direct sequencing. In: *Amyloid and Amyloidosis 1993*, edited by Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, New York, Parthenon Publishing Group Inc., 1994, pp 456–458

69. Holmgren G, Hellman U, Anan I, Lundgren HE, Jonasson J, Stafberg C, Fahoum S, Suhr OB: Cardiomyopathy in Swedish patients with the Gly53Glu and His88Arg transthyretin variants. *Amyloid* 12: 184–188, 2005

70. Booth DR, Gillmore JD, Persey MR, Booth SE, Cafferty KD, Tennent GA, Madhoo S, Cochrane SW, Whitehead TC, Pasvol G, Hawkins PN: Transthyretin Ile73Val is associated with familial amyloidotic polyneuropathy in a Bangladeshi family. Mutations in brief no. 158. Online. *Hum Mutat* 12: 135, 1998

71. Wallace MR, Dwulet FE, Williams EC, Conneally PM, Benson MD: Identification of a new hereditary amyloidosis prealbumin variant, Tyr-77, and detection of the gene by DNA analysis. *J Clin Invest* 81: 189–193, 1988

72. Riboldi G, Del Bo R, Ranieri M, Magri F, Sciacco M, Moggio M, Bresolin N, Corti S, Comi GP: Tyr78Phe transthyretin mutation with predominant motor neuropathy as the initial presentation. *Case Rep Neurol* 3: 62–68, 2011

73. Saito F, Nakazato M, Akiyama H, Kitahara Y, Date Y, Iwasaki Y, Harasawa S, Hisaki R, Horie T, Kinukawa N, Watanabe T, Sakamaki T, Yagi H, Hoshii Y, Yutani C, Kanmatsuse K: A case of late onset cardiac amyloidosis with a new transthyretin variant (lysine 92). *Hum Pathol* 32: 237–239, 2001

74. Kristen AV, Ehlermann P, Helmke B, Hund E, Haberkorn U, Linke RP, Katus HA, Winter P, Altland K, Dengler TJ: Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement. *Amyloid* 14: 283–287, 2007

75. De Lucia R, Mauro A, Di Scapio A, Buffo A, Mortara P, Orsi L, Schiffer D: A new mutation on the transthyretin gene (Ser112 to Ile) causes an amyloid neuropathy with severe cardiac impairment. *Clin Neuropathol* 12: S44, 1993

76. Bergström J, Patrosso MC, Colussi G, Salvadore M, Penco S, Lando G, Marocchi A, Ueda A, Nakamura M, Ando Y: A novel type of familial transthyretin amyloidosis, ATTR Asn124Ser, with co-localization of kappa light chains. *Amyloid* 14: 141–145, 2007

77. Sharma P, Perri RE, Sirven JE, Zeldenrust SR, Brandhagen DJ, Rosen CB, Douglas DD, Mulligan DC, Rakela J, Wiesner RH, Balan V: Outcome of liver transplantation for familial amyloidotic polyneuropathy. *Liver Transpl* 9: 1273–1280, 2003

78. Sekijima Y, Dendle MA, Kelly JW: Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. *Amyloid* 13: 236–249, 2006

79. Miller SR, Sekijima Y, Kelly JW: Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. *Lab Invest* 84: 545–552, 2004

80. Tojo K, Sekijima Y, Kelly JW, Ikeda S: Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. *Neurosci Res* 56: 441–449, 2006

81. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW: The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. [published online ahead of print January 5, 2012] *J Mol Biol* 10.1016/j.jmb.2011.12.060

82. Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Oshima T, Mori Y, Mizuguchi M, Ueda M, Shono M, Obayashi K, Arima H, Ando Y: Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. *Biochem J* 437: 35–42, 2011

83. US National Institutes of Health: Safety, efficacy and pharmacokinetics of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis. Available at www.clinicaltrials.gov/ct2/show/NCT01171859. Accessed March 16, 2012

84. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB: Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. *Nature* 468: 93–97, 2010

85. Macedo B, Magalhães J, Batista AR, Saraiva MJ: Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. *Pharmacol Res* 62: 514–522, 2010

86. Ferreira N, Saraiva MJ, Almeida MR: Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "In vivo" evidence from FAP mice models. *PLoS ONE* 7: e29933, 2012

87. Palhano FL, Leme LP, Busnardo RG, Foguel D: Trapping the monomer of a non-amyloidogenic variant of transthyretin: Exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases. *J Biol Chem* 284: 1443–1453, 2009

88. Nakamura M, Ando Y: [Gene therapy in familial amyloidotic polyneuropathy by single-stranded oligonucleotides (SSOs)]. *Rinsho Byori* 52: 804–812, 2004

89. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW: Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. *Muscle Nerve* 33: 609–618, 2006

90. Alnylam Pharmaceuticals, Inc.: Amyloidosis TTR. Available at www.alnylam.com/Programs-and-Pipeline/Alnylam-5x15/TTR-Amyloidosis.php. Accessed March 16, 2012